Pandemic influenza vaccine & narcolepsy: Simulations on the potential impact of bias by Wijnans, E.G. (Leonoor) et al.
Full Terms & Conditions of access and use can be found at
http://www.tandfonline.com/action/journalInformation?journalCode=ierv20
Download by: [Erasmus University] Date: 13 October 2017, At: 06:58
Expert Review of Vaccines
ISSN: 1476-0584 (Print) 1744-8395 (Online) Journal homepage: http://www.tandfonline.com/loi/ierv20
Pandemic influenza vaccine & narcolepsy:
simulations on the potential impact of bias
Leonoor Wijnans, Caitlin Dodd, Maria de Ridder, Silvana Romio, Daniel
Weibel, Sebastiaan Overeem, Gert Jan Lammers, Jan Bonhoeffer, Steve Black
& Miriam Sturkenboom
To cite this article: Leonoor Wijnans, Caitlin Dodd, Maria de Ridder, Silvana Romio, Daniel
Weibel, Sebastiaan Overeem, Gert Jan Lammers, Jan Bonhoeffer, Steve Black & Miriam
Sturkenboom (2016) Pandemic influenza vaccine & narcolepsy: simulations on the potential impact
of bias, Expert Review of Vaccines, 15:5, 573-584, DOI: 10.1586/14760584.2016.1164045
To link to this article:  http://dx.doi.org/10.1586/14760584.2016.1164045
© 2016 The Author(s). Published by Informa
UK Limited, trading as Taylor & Francis
Group
Accepted author version posted online: 11
Mar 2016.
Published online: 31 Mar 2016.
Submit your article to this journal Article views: 358
View related articles View Crossmark data
Citing articles: 4 View citing articles 
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ABSTRACT
Several studies have identified an association between PandemrixTM, an AS03 adjuvanted pandemic
influenza A(H1N1) vaccine, and narcolepsy, a rare and under-diagnosed sleep disorder with a median
onset-to-diagnosis interval of ten years. This paper reviews potential sources of bias in published
studies and aims to provide, through simulation, methodological recommendations for assessment of
vaccine safety signals. Our simulation study showed that in the absence of an association between the
vaccine and the outcome, presence of detection bias and differential exposure misclassification could
account for elevated risk estimates. These may play a major role, particularly in alert situations when
observation times are limited and the disease has a long latency period. Estimates from the case-control
design were less inflated than those from the cohort design when these biases were present. Overall,
these simulations provide useful insights for the design and interpretation of future studies.
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Background
In August 2010, case reports linking the occurrence of narcolepsy
in children aged 5–19 years to an AS03 adjuvanted H1N1pdm09
(pH1N1) vaccine, PandemrixTM (GlaxoSmithKline, Middlesex, UK)
were published in Finland and Sweden [1,2]. In the European
Union, Pandemrix was widely used, with over 30 million doses
administered. Coverage was particularly high in the Nordic coun-
tries [3]. Following reports from Sweden and Finland, the
European Medicines Agency initiated a review procedure [4]
which eventually led to the restriction of indication for
Pandemrix [5].
Narcolepsy is a chronic sleep disorder that is severely debili-
tating. The dysregulation of the sleep–wake cycle is caused by
the destruction of hypocretin forming neurons in the hypotha-
lamus, which is thought to result from an auto-immune process
[6]. Symptoms include excessive daytime sleepiness (EDS) and
cataplexy [7]. Symptoms usually emerge gradually and can initi-
ally be non-specific. Consequently, symptoms can be attributed
to other diagnoses resulting in a delay of narcolepsy diagnosis
and treatment [8–11]. Despite significant improvements in the
speed and accuracy of narcolepsy diagnosis [10–12], a recent
study found that the median delay between onset and diagnosis
remains approximately 10 years [9].
As of May 2015, eight epidemiological studies testing the
association between Pandemrix and clusters of narcolepsy
cases [13–21] have been published and reporting risk estimates
ranging from 1.6 to 14.4. An overview of the main characteristics
of these studies is presented in Table 1. Generally, published
studies were meticulous in their methods and applied sensitivity
analyses to evaluate the presence of biases. Nonetheless, studies
were inevitably observational and, as studies were mostly
initiated rapidly after the signal emerged, they had limited time
for case capture. Combined with the often nonspecific symp-
toms and onset of narcolepsy resulting in delayed diagnosis
these studies are particularly prone to bias. Five years after the
original signal emerged it remains unclear if and how potential
sources of bias affected the estimates from the association stu-
dies. Consequently it is still unknown what the exact association
between Pandemrix and narcolepsy is [22,23].
It is not unthinkable that a similar scenario could unfold in the
future, that is, a safety signal involving a difficult to diagnose
condition with a delayed onset is linked to exposure with a new
vaccine. Indeed, a similar situation has occurred in the past, when
clusters of cases of Guillain–Barré syndrome were detected after
the introduction of a new swine flu vaccine [24]. Using the
example of narcolepsy and Pandemrix, we explore, in the
absence of a formal hypothesis, the potential impact of two
sources of bias that are likely to occur in similar scenarios.
Detection bias. The first source of bias is a type of selection
bias. Awareness of a potential association between narcolepsy
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and vaccination amongst physicians and the general public
could result in earlier diagnosis for vaccinated cases compared
with unvaccinated cases, making vaccinated cases more likely
to be included in observational studies with limited observa-
tion time [15]. We refer to this as ‘detection bias’.
Differential exposure misclassification. A second source of bias
we consider is a form of recall bias, in which the onset of symp-
toms is misattributed, resulting in misclassification of onset dates
to the period following vaccination. As narcolepsy symptoms
often develop gradually and onset of symptoms is not always
clearly identifiable, studies into narcolepsy are particularly prone
to recall bias. We hypothesize that recalling onset of EDS with
knowledge of a putative association between vaccination and
narcolepsy could lead a patient to recall that symptoms started
after vaccination [25]. We refer to this as ‘differential exposure
misclassification’.
Methods
We considered the impact of detection bias and differential
exposure misclassification as defined above on the association
measure between Pandemrix and narcolepsy.
Simulation
We simulated a population of 100,000 subjects <19 years of
age on 1 April 2009 to mimic the signal-generating popula-
tion. We subsequently simulated dates of birth and death
(based upon average lifespans in Western Europe) to create
a simulated lifetime for each subject. EDS onset dates were
assigned over the lifespan of subjects based upon the
reported age and gender specific incidence rates of narco-
lepsy with cataplexy onset [26]. Given these EDS onset
dates, initial narcolepsy diagnosis dates were assigned
using a random value drawn from a distribution of narco-
lepsy onset-to-diagnosis intervals which was assumed to
have a gamma distribution chosen to mimic the distribution
of onset-to-diagnosis intervals reported in the literature: a
median of 10 years with a range of 0–40 years [11].
Additionally, as the underlying onset-to-diagnosis interval
in children is potentially shorter [10], alternate gamma dis-
tributions with medians of 3 (range 0–13) and 7 (range
0–27) years were also used. All onset-to-diagnosis intervals
were simulated to be at least 40 days long.
Overall vaccination coverage in this populationwas simulated
at 25, 50 and 75%. Vaccination dates were assigned independent
of the age of a subject using a beta distribution of administration
times mimicking real-life Pandemrix administration dates
between 12 October 2009 and 12 February 2010 [27].
A null association (RR = 1) was assumed for the actual
relation between vaccine exposure and outcome.
Detection bias. Reduction in the onset-to-diagnosis interval was
applied only to vaccinated cases for whom initial diagnosis would
occur after the date of media attention (simulated to be 15 August
2010). If EDS onset occurred before 15 August 2010, the reduction
was applied only to the interval from 15 August 2010 to the initial
date of diagnosis. The date of narcolepsy diagnosis was reset in
this way using values drawn from logit-normal distributions with
medians of 30, 60, and 90% (see Figure A1 in appendix) to produce
reductions of the interval, with the restriction that the interval still
was at least 40 days. Data with no reduction (i.e. 0% reduction) in
the interval were also simulated (Figure 1).
Figure 1. Application of detection bias.
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Differential exposure misclassification. Misattribution of EDS
onset dates to the period following vaccination was applied
with probability equal to values drawn from logit-normal dis-
tributions with medians of 30 and 60% (Figure 1) to subjects
who were diagnosed with narcolepsy after vaccination and
after the start of media attention. In this case the onset date
was reset to a random date between the vaccination date and
the minimum of diagnosis date and vaccination date plus 180
days, based upon the 6 month risk period used by Miller et al.
in their self-controlled case series analysis [19]. Data with no
misattribution of onset dates were also simulated (Figure 2).
We simulated nine combinations of the underlying popula-
tion settings: gamma scale (baseline onset-to-diagnosis inter-
val, three different values) and vaccination coverage (three
values), to which we applied 12 combinations of the simulated
sources of bias: detection bias (four values), and differential
exposure misclassification parameters (three values) for a total
of 108 combinations of simulation parameters. Variation in the
underlying population settings (baseline onset-to-diagnosis
interval and vaccination coverage) was conducted in the
absence of a hypothesis regarding the impact of these
changes on effect estimates.
Analysis
The association between vaccination and narcolepsy in chil-
dren aged 4 to <19 years during the study period was ana-
lyzed using dynamic cohort and case–control designs. In the
primary analyses a case capture (study period) of 1 April 2009
to 1 December 2010 was used in line with several published
studies. We calculated absolute incidence rates in 6-month
periods and calculated case counts during exposed and unex-
posed person time to investigate how incidence would
change over time in the presence of detection bias. We addi-
tionally calculated the number of onset dates in exposed and
unexposed person time at each level of each of the two bias
parameters. In the comparative cohort analysis, the incidence
rate of narcolepsy was compared between dynamic cohorts of
vaccinated and non-vaccinated persons. All person time after
the date of vaccination was considered exposed, whereas the
entire case-capture period of non-vaccinated persons as well
as the pre-vaccination time in vaccinated subjects contributed
to non-exposed person time. Rate ratios were calculated
based on Poisson regression. In the case–control analysis,
cases were matched to 10 controls on sex, age in years and
onset date. Odds ratios were calculated using conditional
logistic regression.
We conducted several analyses to investigate the effects of
different design choices and ways to mitigate bias. All sensi-
tivity analyses were conducted using vaccination coverage of
50% and the baseline onset-to-diagnosis interval distribution
described in literature with median 10 years, range 0–40 years.
To study the effect of the length of case-capture period,
analyses with observation periods as long as 50 years were
conducted. To study the effect of exclusion of cases possibly
affected by awareness of a putative association, in one of the
settings we excluded the cases with onset dates and diagnosis
dates after 15 August 2010. Each of these sensitivity analyses
was conducted in the absence of a hypothesis.
For each set of simulation parameters, 500 replications
were analyzed, each producing an estimate and 95% confi-
dence interval. Reported results are the exponentiated median
of these 500 estimates calculated on the log scale and med-
ians of the lower and upper confidence limits. All analyses
were conducted using SAS 9 · 2.
Results
Application of onset-to-diagnosis interval reduction (detection
bias) and differential exposure misclassification over three
coverage rates and three baseline onset-to-diagnosis intervals
increased the number of narcolepsy onset dates observed in
the study period. Figure 3 shows, for exposed and unexposed
children, the number of onset dates associated with narco-
lepsy diagnosed cases in scenarios with different percentages
of differential exposure misclassification (columns), vaccina-
tion coverage (rows) and levels of detection bias (x-axis in
each plot), using a baseline onset-to-diagnosis interval with a
median of 10 (range 0–40) years. The number of observed
narcolepsy onset dates increases at approximately the same
rate in exposed and unexposed person time with an increas-
ing detection bias in the absence of differential exposure
misclassification (within column 1, Figure 3) except when
vaccine coverage is 25% in which case no onset dates are
observed in exposed person time. With the introduction of
differential exposure misclassification in exposed subjects,
new narcolepsy diagnoses occur more often in post-vaccina-
tion person time. The number of onset dates within unex-
posed person time also increases with increased reduction in
the onset-to-diagnosis interval because, in these cases, the
bias is being applied to vaccinated cases who experienced
onset prior to vaccination. Figure 4 shows the effects of reduc-
tion of EDS onset-to-diagnosis date on the shape of incidence
rates over calendar time in this cohort of 0–19 year olds in
2009. With a reduction of 60 or 90% in lag time, a clear peak in
incidence of narcolepsy diagnoses occurs after media atten-
tion. These rates then return to the baseline rate or fall below
the baseline rate because of depletion of cases through early
diagnosis. The primary study period of 1 April 2009 to 1
December 2010 is indeed a period of marked increase in
newly diagnosed cases with reduction in time from onset-to-
diagnosis.
Table 2 shows the results of cohort and case–control ana-
lyses of all 108 different parameter settings.
Because a 10-year onset-to-diagnosis interval has been
reported in the literature, we have chosen to illustrate our
results using underlying populations with this onset-to-diag-
nosis interval and the intermediate vaccine coverage of 50%.
Using a cohort analysis on this underlying population to
which the maximum reduction of time from EDS onset-to-
diagnosis (90%) has been applied in the absence of differential
exposure misclassification produced a median RR of 2.24 (95%
CI: 1.39, 3.62). In case–control analysis, the same simulation
parameter settings produced an OR of 2.99 (95% CI: 1.79, 5.00)
(Table 2).
In the absence of a reduction in the EDS onset-to-diagnosis
interval, differential exposure misclassification resulted in a RR
of 4.31 (95% CI: 1.68, 10.74) when vaccination coverage was
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50% and the EDS date was attributed to the post-vaccination
period with a median probability of 60% for vaccinated cases.
In the case–control analysis, the same simulation parameter
settings produced an OR of 4.16 (95% CI: 1.54, 11.17) (Table 1).
When combining the effect of detection bias and differen-
tial exposure misclassification, the estimates were higher in
cohort analyses than in case–control analyses as the biases
became more pronounced. In the most extreme scenario, with
a median 90% reduction in the onset-to-diagnosis interval in
vaccinated cases and a median probability of differential mis-
classification equal to 60% in vaccinated cases, we found a RR
of 28.4 in the cohort analysis (95% CI: 17.13, 47.12). The same
parameter settings produced an OR of 16.98 (95% CI: 10.15,
43.85) in the case–control analysis (Table 2). In the absence of
either source of bias, median RR estimates from the cohort
analysis for all scenarios were <1 when observation time was
limited. However, with extension of observation time up to
25 years, the RR was estimated to equal to the simulated RR
of 1.
Results from case–control analyses were less inflated than
those from cohort analyses when detection bias and differen-
tial exposure misclassification were present. For both case–
control and cohort designs, increased vaccination coverage
and a shorter baseline onset-to-diagnosis interval lead to RR
estimates closer to the true rate of one when biases are
present (Table 1).
Figure 2. Application of differential exposure misclassification.
Figure 3. Case Counts (Onset dates) occurring in exposed and unexposed person time.
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Extension of the case-capture period reduces the bias
(Figure 5). With each extension, the rate of narcolepsy in
vaccinated subjects converges toward the background rate.
As illustrated in Figure 4, reduction in time from onset-to-
diagnoses leads to incidences greater than the background
rate in the period following awareness of the association in
vaccinated cases, followed by reduction in the incidence rate
to levels below the background rate.
When cases with an onset date after 15 August 2010
were excluded, the RR was 1.87 (95% CI: 1.15, 3.05) in
cohort analyses for the extreme setting of detection bias
in the absence of differential exposure misclassification.
Similarly, the RR was 4.45 (1.76, 11.67) with exclusion of
cases with onset after 15 August 2010 at the most extreme
setting of differential exposure misclassification in the
absence of detection bias. Exclusion of cases with EDS
onset dates after media attention, with a 90% reduction in
the onset-to-diagnosis interval and a 60% probability of
differential exposure misclassification, produced an RR of
27.10 (95% CI: 16.52, 44.11) while the estimate was 28.4
(95% CI: 17.13, 47.12) when these cases were not excluded.
Exclusion of all cases with a diagnosis of narcolepsy after
media attention resulted in estimates <1 and confidence
intervals including 1 for all parameter settings. Excluding
these cases nullified the effect of differential misclassifica-
tion bias because only those cases diagnosed after media
attention were simulated to misattribute their date of EDS
onset to the period following vaccination.
Figure 4. Incidence of new narcolepsy diagnoses over time.
Figure 5. Relative rates of narcolepsy with extended observation periods.
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Discussion
Our results indicate that, in the absence of a real association
between Pandemrix and narcolepsy, the presence of detection
bias or differential exposure misclassification elevates risk
estimates.
In the absence of either source of bias, median RR estimates
from the cohort analysis for all scenarios were less than the
expected value of 1. Our explanation for this observation is as
follows. The study observation period is limited and the interval
between onset and diagnosis can be longer than the study obser-
vation time, therefore, as diagnosis is the criteria for case inclusion,
a number of cases with onset within the observation period will
not be included as cases. However, exposed and unexposed
person time within the cohort is fixed. When we analyzed all
cases with onset within the observation period regardless of
their diagnosis date, the RR = 1. In the absence of either bias,
using diagnosis dates for case capture, an observation period as
long as 25 years would be necessary to obtain the true RR of 1.
We found that biased attribution of EDS onset (differential
exposure misclassification) has a greater impact on the esti-
mates than a reduction in the EDS onset-to-diagnosis interval
(detection bias) both in the cohort and case–control designs.
While detection bias increases the relative risk estimates, the
effect is not discernible until the onset-to-diagnosis interval is
so reduced that many additional cases can be detected in a
short observation period. The simultaneous presence of detec-
tion bias and differential exposure misclassification increases
RRs more rapidly than could be expected by the effect size of
each bias in isolation.
In an attempt to exclude detection bias, several published
studies limited their primary observation period for EDS onset to
the period before media attention [15,18] or included sensitivity
analyses using such a reduced study period [21]. Additionally,
studies used primary index dates that were thought to be less
susceptible to such a bias including onset of symptoms [14,19],
first contact with health care [18,21] or referral to specialist care
[15,20]. In line with observations from our simulations, limiting
analysis to subjects with an onset date prior to media attention
will not eliminate the effect of detection bias, as all patients need
to be diagnosed to be included, which is where the bias arises. To
illustrate this, when limiting cases to those with an EDS date
before media attention, Nohynek et al. found that the RR
increased from 11.4 to 12.7 [18] and O’Flanagan et al. found
that the RR increased from 13.0 to 14.5 [21]. As only diagnosed
subjects can be included as cases, detection bias will be unavoid-
able if the onset-to-diagnosis interval is shorter in vaccinated
individuals. The only way to circumvent the combined effects
of detection bias and differential exposure misclassification
would be to select only patients diagnosed before media atten-
tion. This will result in limited observation time and limited case
inclusion as illustrated by our simulations and as was shown in
the VAESCO study (13). We are not aware of any existing statis-
tical methods to control for detection bias although quantitative
bias analysis could adjust for hypothesized biases [28].
With limited observation time, we found that, in the presence
of detection bias and differential exposure misclassification, esti-
mates from the case–control design are less inflated than those
from the cohort design. The resilience of the case–control in this
scenario has several causes: the outcome is rare and the pool of
controls, matched only by sex and age at onset, is large; also, the
invariability of exposed person time, which is limited by observa-
tion time and vaccine coverage in the cohort approach, is avoided.
Additionally, in this simulated scenario, we were able to sample
controls from the same population as the cases and to assess their
exposure without error, thereby avoiding the most problematic
sources of bias in case–control studies. The only study to date in
which data were analyzed using both a case–control and a cohort
design found lower estimates in the case–control than in the
cohort design [16]. Applying these findings to the interpretation
of all published studies, however, presents a challenge as each
study differed not only in design choice but in many other ways
including underlying population, diagnostic practices, inclusion
and exclusion criteria, and many others. In general, however,
estimates from case–control studies were similar to those from
those cohort studies in which diagnosis was used as an index date.
Those cohort studies which used onset of symptoms as an index
date produced much higher estimates, suggesting presence of
bias, particularly differential exposuremisclassification, a true asso-
ciation in those populations, or both. However, given the com-
plexity of the interplay of design choices and underlying
populations, a meaningful comparison between designs imple-
mented in published studies is not feasible.
Increased vaccination coverage reduced the bias in cohort
and case–control analyses. In cohort analyses, this is explained
by an increase in the person time denominator for vaccinated
cases with a smaller increase in events and, simultaneously, a
decrease in the person time denominator for unvaccinated
cases with a smaller decrease in the number of events. In
case–control analyses, this could be attributed to a greater
probability of matching to vaccinated controls as vaccination
coverage increases, leading in turn to more informative strata
in a conditional analysis.
When a shorter interval from onset-to-diagnosis was
assumed, the impact of simulated biases was less pronounced.
This is because of the fact that, with a shorter onset-to-diag-
nosis interval, more cases, whether vaccinated or not, are
being captured during the study period.
We chose to simulate only those sources of bias for which
data in the absence of a vaccine safety signal exists and for
which simulated variables could be modified to mimic the
bias. Our simulations therefore do not reflect all of the biases
that could potentially affect estimates of an association
between Pandemrix and narcolepsy. For example, it is possible
that non-vaccinated cases also experienced a reduction in the
onset-to-diagnosis interval because of increased awareness of
narcolepsy. However, inclusion of additional simulation para-
meters such as this would have required the making of addi-
tional assumptions for which we had no basis in published
data. By focusing on biases that could be evaluated without
making untenable assumptions, these simulations provide
insights that can improve rapid evaluation of vaccine safety
signals by decision makers. There were several uncertainties,
including the true background rate of narcolepsy and the true
interval between onset of symptoms and diagnosis, for which
we made assumptions in order to conduct our simulations.
The validity of these assumptions will ultimately determine the
robustness of our simulations.
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The introduction of a new vaccine, or an existing vaccine in
new populations, requires the assessment of vaccine safety.
Large numbers of people can be exposed in a relatively short
period providing a challenge to real-time safety surveillance.
In such situations, as illustrated by the experience with
Pandemrix and narcolepsy during the 2009/2010 H1N1 pan-
demic, it can be difficult to determine if a safety finding is a
true association or not. Despite these challenges, the timely
and accurate assessment of potential associations between
adverse events and vaccination are crucial to ensure vaccine
safety and maintain the public’s confidence. We believe that
our simulations provide useful insights for the design and
interpretation of future studies. Importantly, our results illus-
trate that in future analyses of safety signals for diseases with
long latency periods for which observation times are limited
the effect of limited case capture together with fixed person
time denominators should be recognized. Similarly, the
changes in exposed and unexposed person time denomina-
tors with changing vaccination coverage should also be taken
into account. As we have shown, the case–control design
provides less biased estimates in these circumstances as it
does not require the calculation of person time. Moreover,
our simulations illustrate the importance of not only under-
standing background rates of adverse events of special inter-
est prior to vaccination campaigns, but also having insight in
the background onset-to-diagnosis interval.
Recommendations:
● Because rapid assessment of a vaccine safety signal, by
definition, means limited case-capture time, not only the
background incidence of events of interest but the back-
ground onset-to-diagnosis interval should be under-
stood for proper interpretation of risk estimates.
● The impact of differential exposure misclassification in
these simulations underlines the need for accurate and
linkable vaccine registries as well as blinded assessment
of cases.
● When person-time is fixed and the outcome is rare, a
case–control design is more resilient to bias and should
be considered.
Population cohorts should continue to be followed over time
to monitor how rates of narcolepsy change following the
H1N1 pandemic. If these biases were indeed present, we
would expect to see incidence eventually fall back to or
even below the background rate.
To conclude, our results indicate that, in the absence of a
real association between the vaccine and narcolepsy, presence
of detection bias and differential exposure misclassification
could account for elevated RRs in vaccinees in association
studies. While this does not exclude a real increased risk of
narcolepsy following Pandemrix, it is possible that the levels of
increased risk observed were at least partially due to bias.
Expert commentary
When the narcolepsy signal emerged in Sweden and Finland
in 2010, studies had to be started rapidly across Europe in
order to address this signal. Possibilities to evaluate this safety
signals were limited to observational studies which, as a bio-
logical mechanism for the observed adverse event was not
known, involved a great deal of guess work on risk windows,
potential confounding factors and alternative explanations for
observed association. As an answer on the potential associa-
tion between Pandemrix and narcolepsy was needed rapidly,
studies performed had limited follow-up time. They had to do
with the resources available at the time which meant that they
could not always rely on blinded, prospectively collected data
on vaccination for the study population or on detailed pro-
spectively collected data on potential confounding variables
such as underlying comorbidities.
To add to this, suspicion of a potential association between
narcolepsy and Pandemrix was already spreading amongst
healthcare professionals in Finland from as early as February
2010 and was general knowledge after August 2010 when
regulatory agencies published on the association which was
picked up by the media. Knowledge on the association with
vaccination may have resulted in a reduction of the onset-to-
diagnosis interval in vaccinated individuals, whereas this
would not happen to the same extent in non-vaccinated
subjects. Knowledge of a putative association between vacci-
nation and a specific event could also have resulted in
patients placing symptom onset after vaccination.
The simulations described in this article illustrate that in the
absence of a real association between the vaccine and narco-
lepsy presence of detection bias and differential exposure
misclassification could account for the elevated risks detected.
Moreover, the simulations also suggest that it would be too
early to dismiss an elevated risk of narcolepsy following other
influenza vaccines or influenza infection based upon absence
of associations in observational studies alone. The veracity of
the association between narcolepsy and Pandemrix will
become clearer as studies are conducted with longer follow-
up times, especially when studies into potential mechanisms
are taken into account.
The uncertainties surrounding the role Pandemrix may
have played in the surge of narcolepsy diagnoses seen in
several European countries which still exist to date do under-
line the need to improve the infrastructures available in
Europe to monitor vaccine safety and evaluate vaccine safety
signals if these were to emerge. Moreover, they point toward
the need to further develop methods for rapid safety assess-
ment, such as sequential monitoring, and the need to develop
methods which can adjust for stimulated diagnosis in the
presence of awareness. Finally, a systematic assessment of
potential sources of bias and their impact should be an inte-
gral part of any assessment of a safety signal that relies on
observational studies. Without such an assessment great cau-
tion should be exerted before drawing any conclusions from
these studies.
Five-year view
It is not possible to predict when and how a future pandemic
will evolve. Although we might now have considerable experi-
ence to inform the safety profile of the existing influenza
vaccines, with a new pandemic virus and a new mass-vaccina-
tion program we need to be prepared for the occurrence of
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new safety signals. The experience of narcolepsy has taught us
that it is very helpful to have a good understanding not only
of the epidemiology of potential adverse events in Europe but
also of the diagnostic process for these events. It is necessary
to know if there is potential for under diagnosis and what
delays in diagnosis can be expected in different age groups
and in different countries. Although impossible to pinpoint
what adverse events will be of interest, considering the experi-
ence of influenza and (adjuvanted) influenza vaccines focus
should be on neurological events and disorders with a poten-
tial auto-immune etiology. The inter-pandemic period should
be used to collect data on diagnosis rates in different age
groups, populations, countries and improve the understand-
ing of differences between European countries in recording
and diagnosing these conditions.
Key Issues
● Several observational studies have suggested a link
between narcolepsy and Pandemrix, a pandemic influenza
vaccine widely used in Europe during the 2009/2010 influ-
enza A(H1N1) pandemic.
● These studies were conducted during a period of heigh-
tened awareness and, because of the urgent situation in
which they were conducted, had several limitations which
could result in biased estimates.
● We simulated the impact of two potential sources of bias in
a cohort and case–control analysis evaluating the associa-
tion between narcolepsy and exposure to a vaccine.
● The presence of detection bias and differential exposure
misclassification could inflate risk estimates to the degree
observed in several observational studies evaluating the
safety signal.
● Case–control studies were less susceptible to the conse-
quences of detection bias and differential exposure mis-
classification than the cohort study.
● Differential exposure misclassification had a more pro-
nounced impact on risk estimates than detection bias.
● As only diagnosed subjects can be included as cases in any
observational study, it is important to consider the impact
of stimulated diagnosis, especially if the stimulated diagno-
sis is potentially differential on exposure.
● These simulations illustrate the importance of not only
understanding background rates of adverse events of spe-
cial interest prior to vaccination campaigns, but also having
insight in the background onset-to-diagnosis interval.
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Appendix
Figure A1. Logit-Normal distributions from which values of bias parameters were sampled for bias settings of 30, 60, and 90%.
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